<DOC>
	<DOCNO>NCT02258607</DOCNO>
	<brief_summary>This study conduct two phase . The Dose-finding Lead-in Phase , Part A , evaluate safety determine maximum tolerate dose ( MTD ) momelotinib ( MMB ) combine trametinib . Once MTD MMB determine , study proceed Dose-finding Lead-in Phase , Part B , determine MTD trametinib . After MTD establish , study may proceed expansion phase determine efficacy , safety , tolerability MMB combine trametinib MTD participant kirsten rat sarcoma viral oncogene homolog ( KRAS ) mutate metastatic non-small cell lung cancer ( NSCLC ) . Each treatment cycle consist 28 day treatment continue absence disease progression , unacceptable toxicity , consent withdrawal , participant 's refusal treatment .</brief_summary>
	<brief_title>Efficacy Safety Momelotinib Combined With Trametinib Adults With Metastatic KRAS-mutated Non-Small Cell Lung Cancer ( NSCLC ) Who Have Failed Platinum-Based Chemotherapy Preceded Dose-finding Lead-in Phase</brief_title>
	<detailed_description />
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Carcinoma , Non-Small-Cell Lung</mesh_term>
	<mesh_term>Trametinib</mesh_term>
	<criteria>Key Individuals KRASmutated metastatic recurrent nonsmall cell lung cancer Radiologic documentation disease progression Measurable disease per RECIST v1.1 Adequate organ function define follow : Hepatic : Total conjugate bilirubin ≤ 1.25 x upper limit normal ( ULN ) ; aspartate transaminase ( AST ) alanine transaminase ( ALT ) &lt; 3 x upper limit normal ( ULN ) &lt; 5 x ULN set liver metastasis Hematological : Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L , platelet ≥ 100 x 10^9/L , hemoglobin ≥ 9 g/dL Renal : Serum creatinine &lt; 1.5 x ULN OR calculate creatinine clearance ( CLcr ) ≥ 60 ml/min Adequate leave ventricular ejection fraction ( LVEF ) ≥ 50 % Eastern Cooperative Oncology Group ( ECOG ) Performance Status 0 1 Negative serum pregnancy test females Key Less equal 3 week since receive treatment biologic , small molecule , chemotherapy agent nonsmall cell lung cancer 28 day since prior immunotherapy ( nivolumab ) History concurrent second malignancy , except specify exception protocol cancer complete remission ≥ 5 year Known positive status human immunodeficiency virus ( HIV ) Chronic active acute viral hepatitis A , B , C infection hepatitis B C carrier Presence ≥ Grade 2 peripheral neuropathy Brain metastasis , spinal cord compression . Individuals brain metastasis allow treated irradiation surgery , clinically stable without steroid treatment . Individuals document leptomeningeal disease eligible . A history uveitis and/or scleritis Retinal pathology beyond normal agerelated process Evidence retinal vein occlusion ophthalmological exam history retinal vein occlusion History newly diagnose uncontrolled glaucoma/intraocular pressure &gt; 21 mm Hg measure tonography Use daily and/or chronic oral ocular steroid . Individuals must daily steroids least 3 week prior enrol trial History interstitial pneumonitis History long QT syndrome whose corrected QT interval ( QTc ) measure ( Fridericia method ) screen prolong ( &gt; 480 m male female ) . Note : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>